Status:
UNKNOWN
Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients.
Lead Sponsor:
Zhongshan Hospital Xiamen University
Conditions:
Thyroid Cancer, Papillary
Hypothyroidism
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
This project analyzes the relationship between type 2 deiodinase gene polymorphism and the TSH inhibitory treatment efficacy in thyroid cancer patients with thyroidectomy, and explored the factors inf...
Detailed Description
Object: To explore the relationship between type 2 deiodinase gene polymorphism and the TSH inhibitory treatment efficacy in thyroid cancer patients with thyroidectomy, And figure out if it is better ...
Eligibility Criteria
Inclusion
- Age 18-65
- Patients with Hypothyroidism after total thyroidectomy for papillary thyroid carcinoma
- Patients were informed of the study and voluntarily willing to participate.
Exclusion
- Having depression or other mental illness
- Taking drugs that interfere with thyroid hormone absorption for other chronic diseases
- impaired liver function, defined as aspartate aminotransferase (AST) \>3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) \>3x ULN
- impaired renal function ,eGFR: \<45 mL/min (calculated by MDRD formula)
- Recent Cardiovascular Events in a patient:
- (1)Acute Coronary Syndrome (ACS) within 2 months prior to enrolment (2).Hospitalization for unstable angina or acute myocardial infarction within 2 months prior to enrolment (3)Acute Stroke or TIA within two months prior to enrolment (4)Less than two months post coronary artery revascularization 6. Congestive heart failure defined as New York Heart Association (NYHA) class IV, unstable or acute congestive heart failure.
- 7\. Pregnant or breastfeeding women
Key Trial Info
Start Date :
October 18 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05247476
Start Date
October 18 2021
End Date
September 1 2022
Last Update
February 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yan Ling
Xiamen, Fujian, China, 361004